Definium Therapeutics (NASDAQ:DFTX) Stock Price Down 8.1% – Here’s What Happened

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s stock price traded down 8.1% on Monday. The company traded as low as $33.37 and last traded at $33.37. Approximately 506,365 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 2,225,133 shares. The stock had previously closed at $36.33.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on DFTX shares. Wells Fargo & Company increased their price objective on Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. JonesTrading upped their target price on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Wall Street Zen downgraded Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Maxim Group set a $55.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $66.00.

Definium Therapeutics Trading Down 8.0%

The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $37.77 and a 200-day moving average price of $29.51. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of -9.74 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.89). Research analysts predict that Definium Therapeutics, Inc. will post -3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Brandi Roberts sold 3,377 shares of the stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the sale, the chief financial officer directly owned 394,528 shares of the company’s stock, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of the firm’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the sale, the insider owned 494,228 shares in the company, valued at approximately $18,073,917.96. The trade was a 2.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 71,098 shares of company stock valued at $2,626,115. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DFTX. Wellington Management Group LLP acquired a new position in Definium Therapeutics in the 2nd quarter valued at approximately $138,755,000. Seven Fleet Capital Management LP acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth approximately $6,992,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth approximately $812,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Definium Therapeutics during the 2nd quarter worth approximately $1,592,000. Finally, Arizona State Retirement System bought a new stake in shares of Definium Therapeutics during the second quarter valued at approximately $1,431,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.